Biogen Alzheimer’s drug puts FDA’s judgment in harsh spotlight Biogen Inc. said Friday, Jan. 29, that the U.S. Food and Drug Administration is extending its review of aducanumab, an experimental therapy that patients and their families see as a potential lifeline. Written By: Anna Edney / Bloomberg News | 7:45 am, Feb. 2, 2021 × A sign for biotechnology company, Biogen, Inc., is seen on a building in Cambridge, Mass., on March 18, 2017. (Dominick/AFP/Getty Images/TNS) WASHINGTON (Tribune News Service) — A new drug for Alzheimer’s disease is on a tortuous path to...